Ticker News
$NNOX News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
NNOX: Preliminary Q3 revenue $4.3-4.4M; cash ~$26M, going-concern flagged
Nanox reported preliminary unaudited Q3 2026 revenue of approximately $4.3–4.4M (vs $3.4M a year ago), driven by ~$3.1M in teleradiology, $1.0M in AI/software (largely from consolidation of Vaso Health IT) and ~$0.3M in imaging/OEM sales; the company also announced a distribution deal in Italy for its Bone AI and Nanox.ARC X was named a TIME Best Invention of 2026. Management said cash, cash equivalents and deposits were about $26M as of Sept. 30 (down from $60M at year-end 2025), are not sufficient to fund operations for at least one year under current plans, and therefore raise substantial doubt about the company's ability to continue as a going concern without additional financing.
Nanox (NNOX) subsidiary inks distribution deal to sell HealthOST bone-AI in Italy
Nanox AI (subsidiary of Nano‑X Imaging, NNOX) signed a distribution agreement with Technologic s.r.l. (affiliate of Tecnologie Avanzate) to commercialize its HealthOST bone assessment AI in Italy to expand its commercial presence. HealthOST analyzes eligible routine CT scans to provide quantitative and qualitative spine assessments that can help identify patients at risk for osteoporosis and prompt further evaluation, while the partner brings ~50 years of local medtech experience to support market entry.
Nanox's Nanox.ARC X named one of TIME's Best Inventions of 2026
Nanox (NNOX) said its Nanox.ARC X tomosynthesis X‑ray system was named one of TIME’s Best Inventions of 2026. The company notes the device is FDA‑cleared, captures up to 200 coronal images per scan with a claimed ~80% less radiation than CT, runs on standard 110V power with a smaller footprint and plug‑and‑play setup — the TIME recognition could boost commercial visibility as Nanox expands distribution, but the company still faces financial strain and uncertain market acceptance.
NNOX Q2: revenue +37% but $40.7M AI intangible impairment drives large GAAP loss; cash $31.4M, $8.5M raised post-quarter
Nanox (NNOX) reported Q2 2026 revenue of $4.2M (up 37% y/y, driven by consolidation of Nanox Health IT) but recorded a GAAP net loss of $55.5M after taking a $40.7M impairment on AI-related intangible assets; adjusted EBITDA loss was $11.3M, cash was ~$31.4M at quarter-end and the company raised $8.5M post-quarter. Management highlighted commercial progress — expanded U.S. distribution to ten partners, the first Nanox Imaging Network site began patient scans with some insurer reimbursement, new Nanox.AI reseller and pilot programs, and additional capex deployments — while restructuring Korean operations (67% workforce reduction) to target about $2M in annual savings; a securities class-action was filed and is at an early stage.
Nanox signs New England distribution deal to roll out FDA-cleared Nanox.ARC
Nanox’s U.S. unit, Nanox Impact, signed a distribution agreement with Associated X‑Ray Imaging to market, distribute and support the FDA‑cleared Nanox.ARC 3D digital tomosynthesis system across New England using Associated X‑Ray’s regional sales and service infrastructure. The deal expands Nanox’s U.S. channel network to target outpatient and community clinical settings and aims to accelerate commercial deployment, but no financial terms or purchase commitments were disclosed.
Nanox (NNOX) signs exclusive UK reseller deal with Vertec for HealthOST AI bone solution
Nanox AI signed an exclusive three-year sales reseller agreement with Vertec Scientific to commercialize its HealthOST AI bone solution in the United Kingdom, subject to Vertec meeting minimum annual license commitments. HealthOST is FDA‐cleared and UKCA/CE‐marked to analyze routine CT scans opportunistically for vertebral fragility/osteoporosis (no extra imaging required); NICE recommended the technology for NHS use in Nov 2025, and Vertec’s established DXA/bone-health footprint should aid rollout.
Lead-plaintiff deadline Aug 11 in NNOX class action after Q4 impairment and stock drop
A securities law firm reminds Nano‐X (NNOX) investors of a class action and a lead‐plaintiff deadline of August 11, 2026 for purchasers between March 31, 2025 and April 17, 2026. The complaint alleges Nano‐X overstated operational efficiency and demand; the company disclosed on April 20, 2026 a Q4 2025 net loss of $33.4M including a $17.5M impairment tied to a Korean manufacturing restructuring, announced its CFO would step down, and the stock dropped ~24% that day.
Nanox.AI optimizes on‐premise CT imaging AI for Intel Core Ultra processors
Nanox.AI said it optimized its medical imaging AI application framework to run on Intel Core Ultra processors using Intel’s OpenVINO and demonstrated successful, efficient on‐device inference. This enables on‐premise CT AI inference that keeps imaging data inside hospital infrastructure and may ease evaluation and deployment into existing CT workflows, but the company disclosed no commercial deployments, timelines, or quantitative performance metrics.
NNOX hit with securities class action after $17.5M impairment and manufacturing pivot; lead‐plaintiff deadline Aug 11, 2026
SueWallSt (Levi & Korsinsky) notifies Nano‐X Imaging (NNOX) investors of a securities class action covering purchases from March 31, 2025–April 17, 2026 with a lead‐plaintiff deadline of August 11, 2026. The complaint alleges management misled investors about manufacturing efficiency and demand alignment; the alleged fraud was disclosed April 20, 2026 when Nano‐X reported a $17.5M impairment, ~ $18M in restructuring charges, abandonment of in‐house chip manufacturing, a CFO resignation, and a ~24% one‐day share drop and subsequent analyst price‐target cut.
NNOX lead-plaintiff motion deadline Aug 11, 2026 after $17.5M impairment and plant closure triggered 24% drop
A law firm reminder says investors who bought NNOX between March 31, 2025 and April 17, 2026 must file motions by Aug 11, 2026 to seek appointment as lead plaintiff in a securities class action. The suit follows Nano‐X’s disclosure of a $17.5M long‐lived asset impairment and the closure of its South Korea chip line, which coincided with a ~24.4% one‐day share drop on April 20, 2026; absent class members can still participate in any recovery without filing.
NNOX lead-plaintiff filing deadline Aug 11, 2026 after 24% stock drop on $17.5M impairment and Korea plant closure
SueWallSt notifies Nano‐X Imaging (NNOX) investors that the deadline to move to be lead plaintiff in a securities class action is August 11, 2026 after the stock plunged 24.39% on April 20, 2026 when Nano‐X disclosed a $17.5M long‐lived asset impairment and the closure of its South Korea chip manufacturing line. The alleged class covers purchases from March 31, 2025 through April 17, 2026 and claims the company misrepresented manufacturing efficiency and product demand; investors who don’t seek lead status remain class members eligible for any recovery.
Nano‐X investors must act by Aug 11, 2026 to seek lead‐plaintiff role in securities suit
Kirby McInerney LLP reminds Nano‐X (NNOX) investors of the August 11, 2026 deadline to seek the lead‐plaintiff role in a securities class action covering purchases from March 31, 2025 to April 17, 2026. The suit alleges Nano‐X overstated operational efficiency and demand; the company later disclosed a Q4 net loss of $33.4M (including a $17.5M impairment tied to restructuring its Korean chip facility) and announced its CFO will step down — disclosures that sent the stock down ~25% on April 20, 2026.
NNOX: Nanox to present Nanox.AI cardiac study data at SCCT 2026 showing high agreement with experts
Nanox said new data featuring its FDA-cleared Nanox.AI cardiac solution (HealthCCSng) will be presented at SCCT 2026, including initial findings from the multi-site AI INFORM randomized trial and a multi-site analysis comparing AI-detected coronary artery calcium to expert visual assessment. The abstracts report high agreement with expert readings and suggest AI-detected incidental coronary calcium could identify opportunities for preventive lipid‐lowering therapy; posters are scheduled for July 11 and the company is sponsoring a related SCCT session.